- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02955888
Study of Safety, Tolerability & Efficacy in Cystic Fibrosis Patients With Abnormal Glucose Tolerance
A Phase 2, Double-Blind, Placebo Controlled Study to Evaluate the Safety & Tolerability of PBI-4050 and Its Effects on Pancreatic and Pulmonary Function in Cystic Fibrosis Patients With Abnormal Glucose Tolerance
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This is a Phase 2, multi-center, double blind, placebo controlled study to evaluate the safety and tolerability of PBI-4050, and its effects on the pancreatic, pulmonary functions and on various biomarkers in Cystic Fibrosis patients with abnormal glucose tolerance. Patients with abnormal glucose tolerance have elevated glucose level either at 1 hour or 2 hour during an Oral Glucose Tolerance Test (OGTT).
A total of 90 patients will be enrolled for study participation. A Data Safety Monitoring Board (DSMB) will continually review individual patients safety data obtained from the 90 patients. When the first 15 patients have completed at least 1 month of study treatment, the DSMB will meet formally to determine whether additional patients may be enrolled, the study should continue with changes or if the study should be stopped. In addition, the DSMB will review the PK data and may recommend dose adjustment based on the PK results.
The total duration of study participation for each patient is at least 32 weeks, including up to 4 weeks of a screening period, 24 weeks of study treatment and 4 weeks of safety follow-up.
Patients who choose to participate in the open label extension will be in the study for an additional 24 weeks of study treatment and 4 weeks of safety follow-up (for a total of 56 weeks).
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
-
Quebec, Kanada
- Institut Universitaire de Cardiologie et de Pneumologie de l'Université Laval (IUCPQ)
-
-
British Columbia
-
Vancouver, British Columbia, Kanada
- St. Paul's Hospital - Pacific Lung Health Centre (PLHC)
-
-
Nova Scotia
-
Halifax, Nova Scotia, Kanada
- Queen Elizabeth II Health Science Center
-
-
Ontario
-
Ottawa, Ontario, Kanada
- Ottawa Hospital Research Institute
-
Toronto, Ontario, Kanada
- St. Michael's Hospital
-
-
Quebec
-
Montreal, Quebec, Kanada
- Institut de recherches cliniques de Montréal (IRCM)
-
Sherbrooke, Quebec, Kanada
- Centre de recherche du Centre hospitalier Universitaire de Sherbrooke
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Patient is 18 years of age or older at screening.
- Patient has a documented and confirmed CF diagnosis.
- Patient has performed an OGTT for diagnosis of INDENT, IGT and de novo CFRD within 12 months prior to screening visit.
- Patient has a Body Mass Index (BMI) of at least 17 kg/m2.
- Patient has signed written informed consent.
- Patient is able and willing to self-monitor blood glucose level at home.
- Female patients of childbearing potential must have a negative pregnancy test (serum or urine) and agree to use adequate birth control from screening throughout the study and for the 30 days after the last study drug administration.
- If a male patient has not been vasectomized at least 6 months before screening and partners with a woman of childbearing potential, he must be willing to use an acceptable contraceptive method throughout the study and for the 30 days after the last study drug administration.
Exclusion Criteria:
- Patient has recent or ongoing infection requiring intravenous treatment with an anti-infective agent within 30 days before screening.
- Patient is concurrently taking high dose of ibuprofen (>30 mg/kg) or is using corticosteroids (except inhaled and topical corticosteroids).
- Patient is currently using weight-loss medications.
- 4. Patient has used any moderate/potent inhibitor of cytochrome P450 (CYP) 2C9 isozyme or strong inhibitor of CYP3A isozyme within 30 days prior to the first study drug administration.
- Patient has significantly elevated liver enzyme levels, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 2.5 Upper Limit of Normal (ULN) or total bilirubin above ULN at screening.
- Patient has a history of chronic alcohol or other substance abuse as determined at screening that may prevent study compliance based on Investigator judgment.
- History of malignancy of any organ system, treated or untreated, within the past 5 years other than basal or squamous cell skin cancer.
- Patient has unstable chronic heart failure that has required change in therapy within 2 months prior to screening.
- Patient with known non-controlled history of infection with Human Immunodeficiency Virus (HIV) and/or active Hepatitis.
- Woman who is pregnant, breast-feeding or planning a pregnancy during the course of the study.
- Woman of childbearing potential who is unwilling to use adequate birth control throughout the duration of the study.
- Patient has any condition that, in the Investigator's opinion, is likely to interfere with study conduct and compliance.
- Patient has participated in an investigational clinical trial within 30 days (or 5 half-lives, whichever is longer) prior to screening visit.
- Patient is under insulin and/or repaglinide treatment at screening/baseline
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: PBI4050
Fyra 200 mg kapslar (totalt 800 mg) administrerade oralt en gång dagligen.
|
Investigational Medicinal Product
|
Placebo-jämförare: Placebo
Four 200 mg capsules (total 800 mg) administered orally, once daily.
|
Komparator
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Number of Subjects with Adverse Events (Combined Main Study and Extension Study Participation)
Tidsram: Baseline to 1 Year
|
Adverse Event data (including abnormal laboratory values) collected up to final follow-up (30 days after last dose of study drug).
Serious Adverse Events that were ongoing at the follow-up visit will be followed until the event resolved, returned to baseline, or was determined to be a stable or chronic condition.
|
Baseline to 1 Year
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Change from Baseline in glucose level following Oral Glucose Tolerance Test (OGTT) (Combined Main Study and Extension Study Participation)
Tidsram: Up to 1 Year
|
Up to 1 Year
|
Change from Baseline of insulin-secretion following Oral Glucose Tolerance Test (OGTT) (Combined Main Study and Extension Study Participation)
Tidsram: Up 1 Year
|
Up 1 Year
|
Change from Baseline of HbA1C following Oral Glucose Tolerance Test (OGTT) (Combined Main Study and Extension Study Participation)
Tidsram: Up to 1 Year
|
Up to 1 Year
|
Change from Baseline in pulmonary function parameters (FEV1 ) (Combined Main Study and Extension Study Participation)
Tidsram: Up to 1 Year
|
Up to 1 Year
|
Change from Baseline in pulmonary function parameters ( FVC) (Combined Main Study and Extension Study Participation)
Tidsram: Up to 1 Year
|
Up to 1 Year
|
Change from Baseline in pulmonary function parameters (FEV1/FVC ratio) (Combined Main Study and Extension Study Participation)
Tidsram: Up to 1 Year
|
Up to 1 Year
|
Change from Baseline in pulmonary function parameters (Forced Expiratory Flow (FEF25%-75%)) (Combined Main Study and Extension Study Participation)
Tidsram: Up to 1 Year
|
Up to 1 Year
|
Change from baseline in weight (Combined Main Study and Extension Study Participation)
Tidsram: Up to1 Year
|
Up to1 Year
|
Andra resultatmått
Resultatmått |
Tidsram |
---|---|
Changes from baseline in fibrotic and inflammatory biomarkers in blood (Combined Main Study and Extension Study Participation)
Tidsram: Up to 1 Year
|
Up to 1 Year
|
Changes from baseline in fibrotic and inflammatory biomarkers in urine (Combined Main Study and Extension Study Participation)
Tidsram: Up to1 Year
|
Up to1 Year
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studiestol: John Moran, MD, Liminal BioSciences Ltd.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- PBI-4050-CT-9-07
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Cystisk fibros
-
Igdir UniversityOkan UniversityRekryteringDiet, hälsosam | Acne CysticKalkon
-
University of MichiganNational Cancer Institute (NCI); National Institutes of Health (NIH)AvslutadBröstcancer | Mass Cystic | Godartad massaFörenta staterna
-
National Institute of Allergy and Infectious Diseases...Avslutad
-
ProgenaBiomeRekryteringAcne vulgaris | Acne | Acne rosacea | Acne Inversa | Akne Keloidalis | Akne Keloid | Acne Conglobata | Acne Cystic | Acne Pomade | Acne Indurata | Acne Papular | Acne Tropica | Acne Urticata | Acne Fulminans | Akne follikulär | Acne Tropicalis | Acne Detergicans | Akne Jodid | Acne VarioliformisFörenta staterna
Kliniska prövningar på Placebo
-
SamA Pharmaceutical Co., LtdOkändAkut bronkit | Akut övre luftvägsinfektionKorea, Republiken av
-
National Institute on Drug Abuse (NIDA)AvslutadAnvändning av cannabisFörenta staterna
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyAvslutadManliga försökspersoner med typ II-diabetes (T2DM)Tyskland
-
Heptares Therapeutics LimitedAvslutadFarmakokinetik | SäkerhetsfrågorStorbritannien
-
Regado Biosciences, Inc.AvslutadFrisk volontärFörenta staterna
-
Texas A&M UniversityNutraboltAvslutadGlucose and Insulin Response
-
Longeveron Inc.AvslutadHypoplastiskt vänsterhjärtsyndromFörenta staterna
-
ItalfarmacoAvslutadBeckers muskeldystrofiNederländerna, Italien
-
Universidade Estadual de LondrinaConselho Nacional de Desenvolvimento Científico e Tecnológico; Coordination...AvslutadVassleproteintillskott associerat med motståndsträning på hälsoindikatorer hos tränade äldre kvinnorFriska | Kroppssammansättning